British-swedish pharmaceutical company AstraZeneca intends to adjust its German corporate structure to the ever-changing economical and health policy conditions. The company plans to reduce its staff by 400 (down to 625). Affected by those measures will be internal services as well as field services.
Reasons for the cutback in staff are „a modified range of products, deferrals in research and the development of new active ingredients as well as massive state interventions with regards to pricing of innovative medicines.“
In the course of the structural change the number of board members will be reduced as well: in the future management will consist of six divisions instead of eight. Divisions „Commercial Excellence“ and „Strategic Planning“ will be merged into other divisions.
[ilink url=“http://www.pharmazeutische-zeitung.de/index.php?id=nachrichten&type=0&no_cache=1&Nachricht_ID=44381&Nachricht_Title=Nachrichten_AstraZenca%3A+Personalabbau+in+Deutschland“] Link to source (Pharmazeutische Zeitung)[/ilink]